Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dynavax hepatitis B...

    Dynavax hepatitis B vaccine works; raises safety issues: FDA

    Written by Ruby Khatun Khatun Published On 2017-07-29T09:09:30+05:30  |  Updated On 29 July 2017 9:09 AM IST
    Dynavax hepatitis B vaccine works; raises safety issues: FDA

    Dynavax Technologies Corp's experimental hepatitis B vaccine is effective, but there were more deaths and serious heart problems in patients given the vaccine than in those given a rival product, according to a preliminary Food and Drug Administration report published on Wednesday.


    However, overall numbers and rates of such cardiac events were low, the review concluded, and there were limitations in the evaluation of cardiac events that "limits the causal interpretation of these observations."


    The review, posted on the FDA's website, comes two days ahead of a meeting of outside advisors who will discuss the vaccine, Heplisav-B, and recommend whether it should be approved. The FDA is not bound to follow the advice of its advisory panels but typically does so.


    The FDA has twice rejected the product citing unresolved safety concerns. The second rejection, in November, sent Dynavax's shares plunging roughly 70 percent to a year low of $3.20. They have since bounced back and were trading down 0.8 percent at $9.83 on Wednesday.


    Anupam Rama, an analyst at J.P. Morgan, currently estimates the likelihood of approval at 40 percent given the mixed opinions in the FDA's briefing documents and previous rejections, a position that may change following the advisory committee meeting, he said in a research note on Wednesday.


    If the vaccine is approved, Dynavax's shares could rise into the "mid-to-high teens," he added.


    Dynavax argues that the higher number of heart problems, including heart attack, recorded with Heplisav-B is due to fewer than expected instances occurring in the group of patients who took GlaxoSmithKline Plc's Engerix-B.


    One cardiologist consulted by the FDA said the argument "appears plausible" and suggested the imbalance should be noted on the product's label and safety monitoring should continue after it reaches the market. Two other cardiologists were less sure.


    "While the finding could be attributable to chance, I cannot confidently say that there is no increased cardiovascular risk with Heplisav," said one.


    The other stated that Dynavax "cannot/does not fully eliminate the notion that this is a "real" observation worth further investigation. I agree."


    Heplisav-B is designed to enhance the body's immune response to the hepatitis B virus, which can lead to cirrhosis of the liver, cancer and death. The virus is spread through sexual contact, sharing of needles and from mother to child during pregnancy.




    (Reporting by Toni Clarke in Washington; Editing by Frances Kerry)



    Anupam RamacardiacdeathDynavaxDynavax hepatitis B vaccineDynavax's vaccineEngerix-BFDAGlaxoSmithKlinehepatitis BHeplisavHeplisav-BobservationsRaisessafety issuesserious heart problemsvaccine
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok